BiolineRX Announces Positive Results In Celiac Trial

BioLineRx, a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient’s body). The research was published in the February edition of Gastroenterology. The findings indicate that BL-7010 (previously called P(HEMA-co-SS)) reduces digestion of wheat gluten, thereby decreasing its toxicity. View and share